Shots:

• Nanobiotix to receive a $20M up front and is eligible to receive ~$220 M as contingent payments and milestones along with royalties on net sales of NBTXR3 in the licensed countries
• LianBio to get exclusive rights to develop and commercialize NBTXR3 in Greater China- South Korea- Singapore- and Thailand
• LianBio supports the expansion of Nanobiotix’s P-III study evaluating NBTXR3 in patients with LA HNSCC by enrolling 100 patients in China. LianBio has contributed to enroll in additional 5 registrational studies conducted by Nanobiotix across multiple tumor indications and therapeutic combinations including immunotherapy

  Ref: Nanobiotix | Image: Business Wire